OpGen OPGN shares are trading higher after the company announced its Unyvero HPN Panel identifies bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.
"Results obtained by the Unyvero Panel in five hours instead of up to several days by culture methods provides clinicians with an early organism differential, including information on antibiotic resistance markers, allowing earlier treatment decisions and support for antimicrobial stewardship efforts," said OpGen in a press release.
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It's developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs.
OpGen shares were trading 9.05% higher to $2.17 at time of publication on Tuesday. The stock has a 52-week high of $15.20 and a 52-week low of $0.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
